Genotype and Subtype Mapping of the Hepatitis C Virus

Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States. In 2020, an estimate 260,000 deaths were attributable to HCV globally, nearly 80,000 of which occurred in Europe, mainly due to complications such as cirrhosis or hepatocellular carcinoma (HCC). The CARTO-VHC study is a retrospective, observational, multicenter study based on data and samples collected during routine care from 2023 to 2024. The study does not involve direct human participation. The study aims to describe the different genotypes and subtypes of the hepatitis C virus, including unusual subtypes, in a large population of newly diagnosed HCV-positive patients. This will help identify the most common types circulating in France. Additionally, the study will provide a comprehensive understanding of therapeutic failures and drug resistance to direct-acting antivirals (DAA) in treated patients.

NCT Number	NCT07503288
Lead Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions	Hepatitis C Virus, Mutation Abnormality, RNA Positive, Unusual Subtype, Resistance
Enrollment	2,500 participants
Start Date	2026-06-01
Primary Completion	2028-09 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-19